Supplementary Figures – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer

Authors: Future Science Group, Figshare; Halmos, Balazs; Burke, Thomas; Kalyvas, Chrysostomos; Insinga, Ralph; Vandormael, Kristel; Frederickson, Andrew; +1 Authors

doi: 10.25402/imt.19030121 , 10.25402/imt.19030121.v1

Supplementary Figures – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer

- Summary
- Subjects
- Related research
  (15)
- Metrics

Abstract

Figure S1 Kaplan–Meier curves before matching adjustment for a) overall survival b) progression-free survival Figure S2 Forest plot of pembrolizumab versus nivolumab+ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS 1–49% and ≥50%a

Related Organizations

MSD Europe (Belgium)
Belgium
Future Science Group (United Kingdom)
United Kingdom

Keywords

Cancer therapy (excl. chemotherapy and radiation therapy), Solid tumours

15 Research products, page 1 of 2

Indirect Comparison of Pembrolizumab Monotherapy Versus Nivolumab + Ipilimumab in First-Line Metastatic Lung Cancer
2022IsAmongTopNSimilarDocuments
Indirect Comparison of Pembrolizumab Monotherapy Versus Nivolumab + Ipilimumab in First-Line Metastatic Lung Cancer
2022IsSupplementTo
Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials
2022IsAmongTopNSimilarDocuments
Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials
2021IsAmongTopNSimilarDocuments
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
2021IsAmongTopNSimilarDocuments
Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer
2019IsAmongTopNSimilarDocuments
Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials
2022IsAmongTopNSimilarDocuments
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
2022IsAmongTopNSimilarDocuments
Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis
2023IsAmongTopNSimilarDocuments
Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review
2020IsAmongTopNSimilarDocuments

chevron_left
1
2
chevron_right

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average

Found an issue? Give us feedback

0

Average

Beta

SDGs Suggest

3. Good health

Beta

SDGs:

3. Good health,

Related to Research communities

Knowmad Institut

Cancer Research